Spyre Therapeutics 8-K Confirms $350M Offering at $85/Share
SYRE has more than doubled off its 52-week low of $15.86 on elevated volume (3.6× avg).
Summary
Spyre Therapeutics confirmed its $350 million public offering of 4,117,648 shares at $85 per share, with underwriters holding a 30-day option for 617,647 additional shares. Proceeds fund pipeline development including a new SPY072 program for hidradenitis suppurativa.
Key Events · Financing and Capital Events · SYRE
-
$350M Public Offering Priced at $85/Share
On October 5, 2026, an underwriting agreement was entered into to sell 4,117,648 shares of common stock at $85.00 per share, generating approximately $350.0 million in gross proceeds before underwriting discounts and expenses.
-
Underwriter Option for 617,647 Additional Shares
Underwriters received a 30-day option to purchase up to 617,647 additional shares on the same terms, potentially increasing the offering size by approximately $52.5 million if fully exercised.
-
Underwriter Purchase Price Set at $79.90
Underwriters will pay $79.90 per share, representing a $5.10 per share underwriting discount (6.0%) from the $85.00 public offering price.
-
Proceeds Fund Pipeline Including New SPY072 Program
Net proceeds will advance gastroenterology, rheumatology, and dermatology programs, including a new initiative to advance SPY072 into late-stage development for hidradenitis suppurativa, plus general infrastructure and potential in-licensing or acquisitions.
Analysis · SYRE · Life Sciences
A $350 million public offering was formalized through an underwriting agreement with Jefferies, TD Securities, Leerink Partners, and Stifel. The deal prices 4,117,648 shares at $85.00 per share, with underwriters paying $79.90 per share and holding a 30-day option for 617,647 additional shares. Proceeds fund the company's gastroenterology, rheumatology, and dermatology programs, including a new push to advance SPY072 into late-stage development for hidradenitis suppurativa. The offering closes on or about October 7, 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRE was trading at $80.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $15.86 to $110.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.